Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era

Area of Science:

• Cardiology
• Nephrology
• Endocrinology
• Metabolic Syndrome

Background:

• Cardiovascular-kidney-metabolic (CKM) syndrome links obesity, hypertension, hyperlipidemia, type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and cardiovascular disease (CVD).
• CKM syndrome involves interrelated metabolic, renal, and cardiovascular dysfunctions driven by obesity, impaired glucose regulation, and chronic inflammation.
• CKM syndrome contributes significantly to elevated morbidity and mortality.

Purpose of the Study:

• To review the efficacy of cardiorenal protective medications, specifically sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP1-RA), in managing CKM syndrome.
• To synthesize recent literature on the benefits of SGLT2-i and GLP1-RA in CKM syndrome.
• To discuss strategies for equitable access and tailored interventions for CKM syndrome.

Main Methods:

• Literature synthesis of recent studies on SGLT2-i and GLP1-RA in CKM syndrome.
• Analysis of medication efficacy regarding cardiovascular, renal, and metabolic outcomes.
• Review of current challenges and future directions in CKM syndrome pharmacotherapy.

Main Results:

• SGLT2-i agents demonstrate reduced cardiovascular mortality, heart failure hospitalizations, and adverse kidney events, irrespective of T2DM status.
• GLP1-RA agents show significant benefits in weight loss, glycemic control, and reduction of cardiovascular and kidney events.
• Both SGLT2-i and GLP1-RA offer cardiorenal protection in the context of CKM syndrome.

Conclusions:

• SGLT2-i and GLP1-RA are effective therapeutic options for managing CKM syndrome, offering substantial cardiorenal benefits.
• Equitable distribution of these pharmacotherapies is crucial for high-risk populations.
• Further research into precision-based therapeutic frameworks and policy innovations is needed for optimal CKM syndrome management.